Nasdaq:US$15.08 (-0.10) | HKEX:HK$23.78 (-0.42) | AIM:£2.28 (-0.03)
Search
Announcements
12345678
9
101112131415161718
found Documents: 868
Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 May 2020

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program
London: Thursday, May 14, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming AS
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 11 May 2020

Chi-Med to Attend Upcoming Investor Conferences
London: Monday, May 11, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Healt
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Apr 2020

Grant of Share Options under Share Option Scheme
London: Wednesday, April 29, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on April 28, 2020, in accordance with its new incentive policy outlined in its full year results announcement on March 3, 2020, it gr
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 27 Apr 2020

Results of Annual General Meeting
London: Monday, April 27, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2020 were duly pa
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Coverage | 22 Apr 2020

Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings
London: Wednesday, April 22, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib will be presented at the upcoming American Association for Cance
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 21 Apr 2020

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme
London: Tuesday, April  21, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on April  20, 2020, in accordance with the new incentive policy outlined in its full year results announcement on March 3, 2020, it
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Apr 2020

Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors
London: Friday, April 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted two Fast Track Designations for the development of surufatinib, for
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 31 Mar 2020

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China
London: Tuesday, March 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors (“FGFR”), in patients
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 25 Mar 2020

2019 Annual Report and Notice of Annual General Meeting
London: Wednesday, March 25, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/ AIM: HCM) today announces that its 2019 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”) have bee
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 9 Mar 2020

Vesting of awards under the Long Term Incentive Plan
London: Monday, March 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that following the announcement of the 2019 annual results of Chi-Med on March 3, 2020, the following awards granted under the Long Term Incen
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 3 Mar 2020

Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs
Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT   London: Tuesday, March 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM), a commercial-stage biopharmaceutical comp
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 25 Feb 2020

Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions
London: Tuesday, February 25, 2020: Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesd
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Feb 2020

Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium
Press Release London: Monday, February 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combi
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 6 Feb 2020

Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Thursday, February 6, 2020: Hutchiso
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 31 Jan 2020

Chi-Med to Announce 2019 Final Results
The announcement has been updated on February 25, please see the updated announcement here. London: Friday, January 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended Decem
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Jan 2020

TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 23 Jan 2020

Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Thursday, January 23, 2020: Hutchiso
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 21 Jan 2020

Chi-Med Announces Proposed Public Offering of ADSs
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Tuesday, January 21, 2020: Hutchison
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 20 Jan 2020

Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early
London: Monday, January 20, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivotal study of surufatinib in advanced neuroendocrine
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Jan 2020

Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors
Press Release London: Monday, January 13, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase II study in China of surufatinib in combination with Tuoyi (toripalimab) in patients with advanced solid tumors.
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group, Press Releases | 6 Jan 2020

Chi-Med to Present at the 38th Annual JP Morgan Healthcare Conference
Press Release London: Monday, January 6, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcare Conference on Wednes
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2019

Blocklisting Six Monthly Return
London: Tuesday, December 31, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2019

Total Voting Rights
London: Tuesday, December 31, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2019, the issued share capital of Chi-Med consisted of 666,906,450 ordinary shares of US$0.10 ea
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Dec 2019

Chi-Med’s New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China
Press Release London: Friday, December 20, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (“NMPA”) has gran
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 12 Dec 2019

Grant of Share Options under Share Option Scheme
London: Thursday, December 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on December 11, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Nov 2019

Total Voting Rights
London: Friday, November 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 29, 2019, the issued share capital of Chi-Med consisted of 666,886,450 ordinary shares of US$0.10 eac
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Nov 2019

Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China
London: Thursday, November 28, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Elunate® (fruquintinib capsules), its national class 1 targeted anticancer drug for the treatment of patients with advanced
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 25 Nov 2019

Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors
London: Monday, November 25, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug designation to surufatinib for the treatment of pancr
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Nov 2019

Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting
London: Saturday, November 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shared analyses from two clinical studies of savolitinib and fruquintinib at the fifth European Society for Medical Oncology Asia Congress (“ESM
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology | 11 Nov 2019

Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors
London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine
Read More
View Announcement (PDF)
Group, Press Releases | 11 Nov 2019

Chi-Med to Attend Upcoming Investor and Industry Conferences
London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the following conferences: Deutsche Bank Depositary Receipts Virt
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Oct 2019

Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers
London: Thursday, October 17, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent eValuation In gastric cancer basKeT KORea studY) trial in Ca
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 10 Oct 2019

Grant of Share Options under Share Option Scheme
London: Thursday, October 10, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 9, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Me
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Oct 2019

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors
Suzhou, China and London, UK, Thursday, October 10, 2019 — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) and Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration ag
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Oct 2019

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma
London: Friday, October 4, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with relapsed or refr
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Oct 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 30 Sep 2019

CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Monday, September 30, 2019: Hutchison Chin
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 30 Sep 2019

CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Monday, September 30, 2019: Hutchison Chin
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Sep 2019

Total Voting Rights
London: Monday, September 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2019, the issued share capital of Chi-Med consisted of 666,786,450 ordinary shares of US$0.10 e
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Sep 2019

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting
Press Release – Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study – – Preparations underway for the potent
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 25 Sep 2019

Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting
– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented – – Conference call and webcast with lead trial investigators to be held on Mond
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Sep 2019

Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting
London: Wednesday, September 18, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22nd Annual Meeting of the C
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group, Press Releases | 3 Sep 2019

Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley 17th Annual Global Healthcare C
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 Sep 2019

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma
London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Aug 2019

Total Voting Rights
London: Friday, August 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 30, 2019, the issued share capital of Chi-Med consisted of 666,777,450 ordinary shares of US$0.10 each, w
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Aug 2019

Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China
London: Friday, August 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with immune thrombocytopenia (“ITP”
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 20 Aug 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jul 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 30 Jul 2019

Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs
London: Tuesday, July 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.  Major highlight
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Jul 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
Read More
View Announcement (PDF)
12345678
9
101112131415161718